CDTX Company Profile and Key Details

Cidara Therapeutics, Inc. (NASDAQ:CDTX) closed at $220.90 USD, gaining $0.09 (0.04%) from the previous close of $220.80. The stock is currently trading near its 52-week high $15.22 and $221.20. With a market capitalization of about $5.60 billion, Cidara Therapeutics, Inc. is classified as a mid-cap and shows higher-than-market volatility (beta ~1.46). Key stats such as the average daily volume over the past year has been around 1.47 million shares, volume is running light vs its 52-week average. Headquartered in San Diego, CA, Cidara Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jeffrey L. Stein, the company employs approximately 38 people and listed since April 15, 2015. Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States.

Short-term trend indicators are bearishly aligned (SMA20 0.3%, SMA50 36.4%, SMA200 199.35%). The stock’s 14-day RSI is 85.1 (overbought), while the ATR of 3.01 points to moderate volatility. The stock remains hovering near 52-week lows, trading -0.18% below its high and over 1350.72% above its low. Average 10-day trading volume of 1.10 million shares is below the 3-month average of 1.43 million, indicating normal recent market interest.

Cidara Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $28.03. This means the shares are trading above this model’s fair value.

Cidara Therapeutics, Inc. has 25.36 million shares outstanding. The public float is 18.78 million shares, elevated short interest at 8.49% of float. This equals 2.15 million shares. The short ratio is 5.14 days. Institutional investors hold 108.01% of the float. Insiders own 0.89%. RA CAPITAL MANAGEMENT, L.P. holds 3.37 million shares, BIOTECH TARGET N V has 2.30 million shares and Shah Preetam has 227.21 thousand shares. Over the past six months, insider transactions show net selling. They sold 10.43 thousand shares across 2 transactions.

Cidara Therapeutics, Inc. generated EPS of -$11.78 over the past year. Five-year average earnings growth is 1.3%. Wall Street analysts project EPS growth of 38.16% annually over the next five years. The latest quarter delivered EPS of -$3.10. The next quarter is forecast at -$1.58. Next year's EPS is expected at -$88.04. Analyst sentiment is bullish. Analyst rating data shows there are 12 Strong Buy ratings, 15 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $200.00 to $35.00. The high target offers -9.42% upside. The low target suggests -84.15% downside. The mean target is $100.93. This offers -54.29% upside. Cidara Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by 160.5%. The prior quarter beat by -11.76%. Over the last six quarters, Apple has recorded several small beats. These include -47.97% in August 13, 2024.

Our AI price prediction model suggests that Cidara Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 18.67%, with price expected at $262.03 by January 02, 2026, within a range of $221.43 to $300.85 3-Month Outlook: Projected rise of 49.57%, reaching $330.25 by March 19, 2026, with a range of $328.18 to $332.61. 1-Year Outlook: Projected gain of 6.15%, with price at $234.39 by December 18, 2026, within a range of $220.69 to $247.46.

Cidara Therapeutics, Inc. (NASDAQ:CDTX) shares are up 721.43% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Cidara Therapeutics, Inc. trading at a premium to the broader market with a P/E of -32.13. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $50.07, suggesting -77.32% downside. Our AI forecast model points to short-term strength (18.67% over two weeks), a medium-term rise (49.57% over three months), and a longer-term gain (6.15% over one year), with expected trading ranges indicating moderate volatility.

Cidara Therapeutics, Inc. trades at a P/E ratio of -32.13, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 14.05 reflecting a rich premium to book value. The P/FCF stands at -42.12, also below market averages. Compared to sector medians, Cidara Therapeutics, Inc. P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.